Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fesoterodine→

Fesoterodine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
286930-02-7
Molecular formula
C26H37NO3
Molecular weight
411.6 g/mol
Drug class
Muscarinic acetylcholine receptor antagonisturinary antispasmodic
Mechanism of action
Fesoterodine is converted to the active metabolite 5-hydroxymethyl tolterodine, which competitively antagonises muscarinic receptors in the bladder, reducing detrusor overactivity and urinary urgency.
Indications / reported uses
  • Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency and urinary frequency
  • Treatment of neurogenic detrusor overactivity in selected paediatric patients aged 6 years and older weighing more than 25 kg under the US product indication

Sources: US DailyMed — TOVIAZ (fesoterodine) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fesoterodine Environmental Risk Assessment (ERA) (the Fesoterodine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.